- Pulse Biosciences ( NASDAQ: PLSE ) said that new data on its CellFX System, based on the company' Nano-Pulse Stimulation technology, led to clearance of low-risk basal cell carcinoma lesions .
- The technology use nonthermal energy to clear lesions with a lower likelihood of scar formation compared to excisional surgery using electrodesiccation and curettage or Mohs micrographic surgery, the current standards of care for these lesions.
- A video presentation on the results will take place at the American Society for Dermatologic Surgery Annual Meeting which runs Oct. 6-10.
- Seeking Alpha's Quant Rating views Pulse ( PLSE ) as a hold with high marks for momentum and revisions .
For further details see:
Pulse Biosciences reports positive data on CellFX System for basal cell carcinoma lesions